Chromeceptin

CAS No. 331859-86-0

Chromeceptin ( 2-amino-7-(dimethylamino)-4-[3-(trifluoromethyl)phenyl]-4H-chromene-3-carbonitrile )

Catalog No. M28518 CAS No. 331859-86-0

Chromeceptin is an inhibitor of the IGF signaling pathway, decreases the numbers of tumorsphere, and inhibits the AKT/mTOR pathway.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 40 Get Quote
5MG 65 Get Quote
10MG 102 Get Quote
25MG 215 Get Quote
50MG 312 Get Quote
100MG 484 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Chromeceptin
  • Note
    Research use only, not for human use.
  • Brief Description
    Chromeceptin is an inhibitor of the IGF signaling pathway, decreases the numbers of tumorsphere, and inhibits the AKT/mTOR pathway.
  • Description
    Chromeceptin is an inhibitor of the IGF signaling pathway, decreases the numbers of tumorsphere, and inhibits the AKT/mTOR pathway.(In Vitro):In Hep3B-derived TS cells, Chromeceptin (5 μM) inhibits IGF2 expression in a time-dependent manner. Chromeceptin suppresses IGF-2 expression at mRNA and protein levels in HCC cells.
  • Synonyms
    2-amino-7-(dimethylamino)-4-[3-(trifluoromethyl)phenyl]-4H-chromene-3-carbonitrile
  • Pathway
    Cytoskeleton/Cell Adhesion Molecules
  • Target
    Akt
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    331859-86-0
  • Formula Weight
    359.4
  • Molecular Formula
    C19H16F3N3O
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    N#CC1=C(OC2=CC(=CC=C2C1C3=CC=CC(=C3)C(F)(F)F)N(C)C)N
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • 3CAI

    3CAI is a potent and specific AKT1 and AKT2 inhibitor.

  • Ch-319

    Ch-319 (Ch319) is a triphenyltin (IV) carboxylate derivative that modulates AKT/FOXO3a signaling and inhibits progression of prostate cancer.

  • AT7867

    AT7867 is a potent, ATP-competitive, orally available dual Akt and p70S6K inhibitor with Ki of 17-85 nM, also inhibits PKA with Ki of 20 nM.